Heart failure with reduced EF — RCPSC IM MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Initiate foundational disease-modifying therapy with ARNI, MRA and SGLT2 inhibitor as tolerated
Contemporary HFrEF care uses foundational disease-modifying therapy including ARNI or ACE inhibitor pathway, evidence beta-blocker, MRA and SGLT2 inhibitor, introduced and titrated as tolerated. Diuretics improve congestion but do not replace these therapies.
Reference: Canadian Cardiovascular Society heart failure guideline updates